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Background
We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with enalapril 
in patients who had heart failure with a reduced ejection fraction. In previous stud-
ies, enalapril improved survival in such patients.
Methods
In this double-blind trial, we randomly assigned 8442 patients with class II, III, or 
IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at 
a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addi-
tion to recommended therapy. The primary outcome was a composite of death from 
cardiovascular causes or hospitalization for heart failure, but the trial was designed 
to detect a difference in the rates of death from cardiovascular causes.
Results
The trial was stopped early, according to prespecified rules, after a median follow-
up of 27 months, because the boundary for an overwhelming benefit with LCZ696 
had been crossed. At the time of study closure, the primary outcome had occurred 
in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the 
enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval 
[CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 
patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 
0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), 
respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 
0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospi-
talization for heart failure by 21% (P<0.001) and decreased the symptoms and 
physical limitations of heart failure (P = 0.001). The LCZ696 group had higher pro-
portions of patients with hypotension and nonserious angioedema but lower pro-
portions with renal impairment, hyperkalemia, and cough than the enalapril group.
Conclusions
LCZ696 was superior to enalapril in reducing the risks of death and of hospitaliza-
tion for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov num-
ber, NCT01035255.)
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A ngiotensin-converting–enzyme (ACE) inhibitors have been the corner-stone of the treatment for heart failure 
and a reduced ejection fraction for nearly 25 
years, since enalapril was shown to reduce the 
risk of death in two trials.1,2 Long-term treat-
ment with enalapril decreased the relative risk of 
death by 16% among patients with mild-to-mod-
erate symptoms.2 The effect of angiotensin- 
receptor blockers (ARBs) on mortality has been 
inconsistent,3,4 and thus, these drugs are recom-
mended primarily for patients who have unac-
ceptable side effects (primarily cough) while re-
ceiving ACE inhibitors. Subsequent studies 
showed that the use of beta-blockers and miner-
alocorticoid-receptor antagonists, when added to 
ACE inhibitors, resulted in incremental decreases 
in the risk of death of 30 to 35% and 22 to 30%, 
respectively.5-9
Neprilysin, a neutral endopeptidase, degrades 
several endogenous vasoactive peptides, includ-
ing natriuretic peptides, bradykinin, and adre-
nomedullin.10-12 Inhibition of neprilysin increas-
es the levels of these substances, countering the 
neurohormonal overactivation that contributes 
to vasoconstriction, sodium retention, and mal-
adaptive remodeling.13,14 Combined inhibition of 
the renin–angiotensin system and neprilysin had 
effects that were superior to those of either ap-
proach alone in experimental studies,15,16 but in 
clinical trials, the combined inhibition of ACE 
and neprilysin was associated with serious an-
gioedema.17,18
LCZ696, which consists of the neprilysin in-
hibitor sacubitril (AHU377) and the ARB valsar-
tan, was designed to minimize the risk of serious 
angioedema.19,20 In small trials involving pa-
tients who had hypertension or heart failure with 
a preserved ejection fraction, LCZ696 had hemo-
dynamic and neurohormonal effects that were 
greater than those of an ARB alone.21,22 We ex-
amined whether the long-term effects of LCZ696 
on morbidity and mortality were superior to those 
of ACE inhibition with enalapril in patients 
with chronic heart failure and a reduced ejection 
fraction.
Me thods
Study Oversight
The executive committee designed and oversaw 
the conduct of the trial and data analysis in col-
laboration with the sponsor, Novartis. The trial 
was reviewed by an independent data and safety 
monitoring committee. Data were collected, man-
aged, and analyzed by the sponsor according to a 
predefined statistical analysis plan, and the anal-
yses were replicated by an independent academic 
statistician. The first draft of the manuscript was 
prepared by the first two authors, who had unre-
stricted access to the data, and was reviewed and 
edited by all the authors. All the authors made 
the decision to submit the manuscript for publi-
cation and assume responsibility for the accuracy 
and completeness of the analyses.
Study Design
The study design has been reported previous-
ly.23,24 The trial protocol and the statistical analy-
sis plan (included in the Supplementary Appen-
dix) are available with the full text of this article 
at NEJM.org. The trial was approved by the ethics 
committee at each study center. All the patients 
provided written informed consent.
The study consisted of three phases: the screen-
ing period; a single-blind run-in period during 
which all patients received enalapril, which was 
followed by a single-blind run-in period during 
which all patients received LCZ696, to ensure an 
acceptable side-effect profile of the study drugs at 
target doses; and double-blind treatment in the 
two study groups.
Study Patients
Eligibility requirements at screening included an 
age of at least 18 years, New York Heart Association 
(NYHA) class II, III, or IV symptoms, and an ejec-
tion fraction of 40% or less (which was changed 
to 35% or less by an amendment to the protocol 
on December 15, 2010). Patients were required to 
have a plasma B-type natriuretic peptide (BNP) 
level of at least 150 pg per milliliter (or an N-termi-
nal pro-BNP [NT-proBNP] level ≥600 pg per mil-
liliter) or, if they had been hospitalized for heart 
failure within the previous 12 months, a BNP of 
at least 100 pg per milliliter (or an NT-proBNP 
≥400 pg per milliliter). Patients taking any dose 
of an ACE inhibitor or ARB were considered for 
participation, but for at least 4 weeks before screen-
ing, patients were required to take a stable dose of 
a beta-blocker and an ACE inhibitor (or ARB) equiv-
alent to at least 10 mg of enalapril daily.23
Exclusion criteria included symptomatic hypo-
tension, a systolic blood pressure of less than 
A video summary 
is available at 
NEJM.org 
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100 mm Hg at screening or 95 mm Hg at random-
ization, an estimated glomerular filtration rate 
(eGFR) below 30 ml per minute per 1.73 m2 of 
body-surface area at screening or at randomization 
or a decrease in the eGFR of more than 25% 
(which was amended to 35%) between screening 
and randomization, a serum potassium level of 
more than 5.2 mmol per liter at screening (or 
above 5.4 mmol per liter at randomization), or a 
history of angioedema or unacceptable side ef-
fects during receipt of ACE inhibitors or ARBs.
Study Procedures
Eligible patients were switched from the ACE in-
hibitor or ARB that they had been receiving to 
single-blind treatment with enalapril (at a dose 
of 10 mg twice daily) for 2 weeks. If no unaccept-
able side effects occurred, this regimen was fol-
8442 Underwent randomization
9419 Entered LCZ696 run-in phase
(median duration, 29 days; IQR, 26–35)
977 Discontinued study
547 (5.8%) Had adverse event
58 (0.6%) Had abnormal laboratory
or other test result
100 (1.1%) Withdrew consent
146 (1.6%) Had protocol deviation, 
had administrative problem, or 
were lost to follow-up
47 (0.5%) Died
79 (0.8%) Had other reasons
10,513 Patients entered enalapril run-in phase
(median duration, 15 days; IQR, 14–21)
1102 Discontinued study
591 (5.6%) Had adverse event
66 (0.6%) Had abnormal laboratory
or other test result
171 (1.6%) Withdrew consent
138 (1.3%) Had protocol deviation, 
had administrative problem, or 
were lost to follow-up
49 (0.5%) Died
87 (0.8%) Had other reasons
4187 Were assigned to receive LCZ696
4176 Had known final vital status
11 Had unknown final vital status
4212 Were assigned to receive enalapril
4203 Had known final vital status
9 Had unknown final vital status
43 Were excluded
6 Did not undergo valid randomization
37 Were from four sites prematurely
closed because of major GCP violations
Figure 1. Screening Criteria, Run-in Periods, and Randomization.
The proportion of patients who withdrew from the study because of adverse events was higher during the enalapril 
run-in period than during the LCZ696 run-in period after adjustment for the longer duration of LCZ696 exposure. 
The most common reasons for withdrawal from the study during the run-in period were hypotension, cough, hyper-
kalemia, and renal dysfunction. During the run-in period, 8 patients did not take enalapril and took only LCZ696. 
IQR denotes interquartile range, and GCP Good Clinical Practice.
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lowed by single-blind treatment with LCZ696 for 
an additional 4 to 6 weeks (initially at a dose of 
100 mg twice daily, which was increased to 200 mg 
twice daily). (The ARB component of the 200-mg 
dose of LCZ696 is equivalent to 160 mg of valsar-
tan.) During this run-in period, to minimize the 
risk of angioedema caused by overlapping ACE 
and neprilysin inhibition, enalapril was withheld a 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
LCZ696
(N = 4187)
Enalapril
(N = 4212)
Age — yr 63.8±11.5 63.8±11.3
Female sex — no. (%) 879 (21.0) 953 (22.6)
Race or ethnic group — no. (%)†
White 2763 (66.0) 2781 (66.0)
Black 213 (5.1) 215 (5.1)
Asian 759 (18.1) 750 (17.8)
Other 452 (10.8) 466 (11.1)
Region — no. (%)
North America 310 (7.4) 292 (6.9)
Latin America 713 (17.0) 720 (17.1)
Western Europe and other‡ 1026 (24.5) 1025 (24.3)
Central Europe 1393 (33.3) 1433 (34.0)
Asia–Pacific 745 (17.8) 742 (17.6)
Systolic blood pressure — mm Hg 122±15 121±15
Heart rate — beats/min 72±12 73±12
Body-mass index§ 28.1±5.5 28.2±5.5
Serum creatinine — mg/dl 1.13±0.3 1.12±0.3
Clinical features of heart failure
Ischemic cardiomyopathy — no. (%) 2506 (59.9) 2530 (60.1)
Left ventricular ejection fraction — % 29.6±6.1 29.4±6.3
Median B-type natriuretic peptide (IQR) — pg/ml 255 (155–474) 251 (153–465)
Median N-terminal pro–B-type natriuretic peptide (IQR)  
— pg/ml
1631 (885–3154) 1594 (886–3305)
NYHA functional class — no. (%)¶
I 180 (4.3) 209 (5.0)
II 2998 (71.6) 2921 (69.3)
III 969 (23.1) 1049 (24.9)
IV 33 (0.8) 27 (0.6)
Missing data 7 (0.2) 6 (0.1)
Medical history — no. (%)
Hypertension 2969 (70.9) 2971 (70.5)
Diabetes 1451 (34.7) 1456 (34.6)
Atrial fibrillation 1517 (36.2) 1574 (37.4)
Hospitalization for heart failure 2607 (62.3) 2667 (63.3)
Myocardial infarction 1818 (43.4) 1816 (43.1)
Stroke 355 (8.5) 370 (8.8)
Pretrial use of ACE inhibitor‖ 3266 (78.0) 3266 (77.5)
Pretrial use of ARB‖ 929 (22.2) 963 (22.9)
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day before the initiation of treatment with LCZ696, 
and LCZ696 was withheld a day before random-
ization.
Patients who had no unacceptable side effects 
of the target doses of the two study medications 
were randomly assigned in a 1:1 ratio to double-
blind treatment with either enalapril (at a dose 
of 10 mg twice daily) or LCZ696 (at a dose of 
200 mg twice daily) with the use of a computer-
ized randomization system involving concealed 
study-group assignments. Patients were evaluated 
every 2 to 8 weeks during the first 4 months of 
double-blind therapy and every 4 months there-
after. The dose of the study drug could be reduced 
in patients who had unacceptable side effects at 
target doses.
Study Outcomes
The primary outcome was a composite of death 
from cardiovascular causes or a first hospitaliza-
tion for heart failure. The secondary outcomes were 
the time to death from any cause, the change from 
baseline to 8 months in the clinical summary score 
on the Kansas City Cardiomyopathy Questionnaire 
(KCCQ)25 (on a scale from 0 to 100, with higher 
scores indicating fewer symptoms and physical 
limitations associated with heart failure), the 
time to a new onset of atrial fibrillation, and the 
time to the first occurrence of a decline in renal 
function (which was defined as end-stage renal 
disease or as a decrease in the eGFR of at least 
50% or a decrease of more than 30 ml per minute 
per 1.73 m2 from randomization to less than 60 ml 
per minute per 1.73 m2). Adjudication of these 
outcomes was carried out in a blinded fashion by 
a clinical-end-points committee according to pre-
specified criteria.
Statistical Analysis
We estimated that the annual rate of the primary 
end point would be 14.5% and the rate of death 
from cardiovascular causes would be 7.0% in the 
enalapril group. Calculation of the sample size was 
based on mortality from cardiovascular causes. We 
estimated that we would need to follow approxi-
mately 8000 patients for 34 months, with 1229 
deaths from cardiovascular causes, to provide 
the study with a power of 80% to detect a relative 
reduction of 15% in the risk of death from car-
diovascular causes in the LCZ696 group, at an 
overall two-sided alpha level of 0.05. On the basis 
of these calculations, we estimated that the pri-
mary end point would occur in 2410 patients, 
which would provide a power of 97% to detect a 
15% reduction in the risk of this outcome.
The data and safety monitoring committee 
Table 1. (Continued.)
Characteristic
LCZ696
(N = 4187)
Enalapril
(N = 4212)
Treatments at randomization — no. (%)
Diuretic 3363 (80.3) 3375 (80.1)
Digitalis 1223 (29.2) 1316 (31.2)
Beta-blocker 3899 (93.1) 3912 (92.9)
Mineralocorticoid antagonist 2271 (54.2) 2400 (57.0)
Implantable cardioverter–defibrillator 623 (14.9) 620 (14.7)
Cardiac resynchronization therapy 292 (7.0) 282 (6.7)
* Plus–minus values are means ±SD. There were no significant differences between the two groups except for the use of 
digitalis (P = 0.04) and mineralocorticoid-receptor antagonists (P = 0.01), with values not adjusted for multiple testing. 
Percentages may not total 100 because of rounding. More details about the baseline characteristics are provided in 
Section 3 in the Supplementary Appendix. To convert the values for creatinine to micromoles per liter, multiply by 88.4. 
IQR denotes interquartile range.
† Race or ethnic group was reported by the investigators.
‡ This category includes South Africa and Israel.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ The data for New York Heart Association (NYHA) class reflect the status of patients at the time of randomization. Patients 
were required to have at least NYHA class II symptoms at screening.
‖ At the screening visit, 20 patients were not receiving the protocol-required treatment with an angiotensin-converting–
enzyme (ACE) inhibitor or an angiotensin-receptor blocker (ARB), and 45 patients were taking both drugs. Doses of 
pretrial ACE inhibitors and ARBs are provided in the Supplementary Appendix.
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specified that three interim efficacy analyses 
should be conducted after the accrual of one 
third, one half, and two thirds of the events, and 
the statistical stopping guideline for a compel-
ling benefit required a one-sided nominal P value 
of less than 0.0001 at the first analysis and less 
than 0.001 at the second and third analyses in 
favor of LCZ696 for both death from cardiovas-
cular causes and the primary end point. On 
March 28, 2014, at the third interim analysis 
(after enrollment had been completed), the com-
mittee informed the two coprincipal investiga-
tors that the prespecified stopping boundary for 
an overwhelming benefit had been crossed. The 
executive committee voted to stop the trial and 
selected March 31, 2014, as the cutoff date for 
all efficacy analyses; the sponsor accepted this 
decision.
We included data from all patients who had 
undergone a valid randomization in the analyses 
of the primary and secondary outcomes, accord-
ing to the intention-to-treat principle. A sequen-
tially rejective procedure was used for analysis of 
the secondary efficacy end points, with the first 
two secondary end points at the highest level of 
the testing sequence. (For details, see the statisti-
cal analysis plan in the Supplementary Appendix.) 
Time-to-event data were evaluated with the use 
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Figure 2. Kaplan–Meier Curves for Key Study Outcomes, According to Study Group.
Shown are estimates of the probability of the primary composite end point (death from cardiovascular causes or first hospitalization for 
heart failure) (Panel A), death from cardiovascular causes (Panel B), first hospitalization for heart failure (Panel C), and death from any 
cause (Panel D).
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of Kaplan–Meier estimates and Cox proportional-
hazards models, with treatment and region as 
fixed-effect factors; hazard ratios, 95% confi-
dence intervals, and two-sided P values were 
calculated with the use of the Cox models. We 
assessed the consistency of the treatment effect 
among 18 prespecified subgroups and used a 
repeated-measures covariance model to evalu-
ate the KCCQ score, with baseline values, study 
group, region, study visit, and the interaction 
between study visit and study group as covari-
ates; a score of zero was used for patients who 
had died. We used Fisher’s exact test to compare 
rates of adverse events. Data on symptomatic 
hypotension, worsening renal function, hyper-
kalemia, cough, and angioedema were collected 
prospectively as events of interest.
R esult s
Study Patients
From December 8, 2009, through November 23, 
2012, a total of 10,521 patients at 1043 centers in 
47 countries entered the run-in period. Of these 
patients, 2079 did not fulfill the criteria for ran-
domization, and 43 patients underwent random-
ization erroneously or were enrolled at sites that 
were closed owing to serious Good Clinical Prac-
tice violations; these patients were prospectively 
omitted from all analyses before the end of the 
trial. Accordingly, 4187 patients were randomly 
assigned to receive LCZ696 and 4212 to receive 
enalapril for the intention-to-treat analysis (Fig. 1). 
The groups were balanced with respect to base-
line characteristics. Most patients were receiving 
recommended pharmacologic therapy for chron-
ic heart failure (Table 1).
Study-Drug Administration and Follow-Up
Except for discontinuations owing to death, the 
study drug was discontinued in 746 patients (17.8%) 
receiving LCZ696 and 833 patients (19.8%) receiv-
ing enalapril (P = 0.02). At the last assessment, 
among patients taking the study medication, the 
mean (±SD) doses in the LCZ696 and enalapril 
groups were 375±71 mg and 18.9±3.4 mg, respec-
tively. Eleven patients in the LCZ696 group and 
9 patients in the enalapril group were lost to 
follow-up, and their data were censored at the 
last contact. The median duration of follow-up 
was 27 months, with no significant between-
group difference.
Table 2. Primary and Secondary Outcomes.*
Outcome
LCZ696
(N = 4187)
Enalapril
(N = 4212)
Hazard Ratio  
or Difference  
(95% CI) P Value
Primary composite outcome — no. (%)
Death from cardiovascular causes or first 
hospitalization for worsening heart failure
914 (21.8) 1117 (26.5) 0.80 (0.73–0.87) <0.001
Death from cardiovascular causes 558 (13.3) 693 (16.5) 0.80 (0.71–0.89) <0.001
First hospitalization for worsening heart failure 537 (12.8) 658 (15.6) 0.79 (0.71–0.89) <0.001
Secondary outcomes — no. (%)
Death from any cause 711 (17.0) 835 (19.8) 0.84 (0.76–0.93) <0.001
Change in KCCQ clinical summary score at 8 mo† −2.99±0.36 −4.63±0.36 1.64 (0.63–2.65) 0.001
New-onset atrial fibrillation‡ 84 (3.1) 83 (3.1) 0.97 (0.72–1.31) 0.83
Decline in renal function§ 94 (2.2) 108 (2.6) 0.86 (0.65–1.13) 0.28
* Hazard ratios were calculated with the use of stratified Cox proportional-hazard models. P values are two-sided and were calculated by 
means of a stratified log-rank test without adjustment for multiple comparisons.
† Scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) range from 0 to 100, with higher scores indicating fewer symptoms and 
physical limitations associated with heart failure. The treatment effect is shown as the least-squares mean (±SE) of the between-group dif-
ference.
‡ A total of 2670 patients in the LCZ696 group and 2638 patients in the enalapril group who did not have atrial fibrillation at the randomiza-
tion visit were evaluated for new-onset atrial fibrillation during the study.
§ A decline in renal function was defined as end-stage renal disease or a decrease of 50% or more in the estimated glomerular filtration rate 
(eGFR) from the value at randomization or a decrease in the eGFR of more than 30 ml per minute per 1.73 m2, to less than 60 ml per min-
ute per 1.73 m2.
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Study Outcomes
Death from cardiovascular causes or hospitaliza-
tion for heart failure (the primary end point) oc-
curred in 914 patients (21.8%) in the LCZ696 
group and 1117 patients (26.5%) in the enalapril 
group (hazard ratio in the LCZ696 group, 0.80; 
95% confidence interval [CI], 0.73 to 0.87; P<0.001 
[exact P = 4.0×10−7]) (Fig. 2A and Table 2). The 
difference in favor of LCZ696 was seen early in 
the trial and at each interim analysis.
A total of 558 deaths (13.3%) in the LCZ696 
group and 693 (16.5%) in the enalapril group 
were due to cardiovascular causes (hazard ratio, 
0.80; 95% CI, 0.71 to 0.89; P<0.001) (Fig. 2B and 
Table 2). Of the patients receiving LCZ696, 537 
(12.8%) were hospitalized for heart failure, as 
compared with 658 patients (15.6%) receiving 
enalapril (hazard ratio, 0.79; 95% CI, 0.71 to 0.89; 
P<0.001) (Fig. 2C and Table 2). Over the duration 
of the trial, the numbers of patients who would 
need to have been treated to prevent one primary 
event and one death from cardiovascular causes 
were 21 and 32, respectively.
A total of 711 patients (17.0%) in the LCZ696 
group and 835 patients (19.8%) in the enalapril 
group died (hazard ratio for death from any cause, 
0.84; 95% CI, 0.76 to 0.93; P<0.001) (Fig. 2D and 
Table 2). The effect of LCZ696 was consistent 
across all prespecified subgroups. A nominally 
significant interaction between NYHA class at 
randomization and the effect of treatment on 
the primary end point (P = 0.03, without adjust-
ment for multiple comparisons) was not seen for 
the interaction between NYHA class and the ef-
fect on death from cardiovascular causes (P = 0.76) 
(Fig. 3).
The mean change from baseline to month 8 
in the KCCQ clinical summary score was a re-
duction of 2.99 points in the LCZ696 group and 
a reduction of 4.63 points in the enalapril group 
(between-group difference, 1.64 points; 95% CI, 
0.63 to 2.65; P = 0.001). When zero values were 
not imputed for patients who died, the score 
improved in the LCZ696 group and declined in 
the enalapril group, and the between-group dif-
ference (0.95 points; 95% CI 0.31 to 1.59) re-
mained significant (P = 0.004).
New-onset atrial fibrillation developed in 84 
patients in the LCZ696 group and 83 patients in 
the enalapril group (P = 0.84) (Table 2). A total of 
94 patients in the LCZ696 group and 108 patients 
in the enalapril group had a protocol-defined de-
cline in renal function (P = 0.28) (Table 2); 8 pa-
tients in the LCZ696 group and 16 in the enalapril 
group had progression to end-stage renal disease 
(P = 0.11).
Safety
Four patients (two in each group) did not start 
the study medication and were excluded from the 
safety analyses. During the run-in period, 12.0% 
of the patients withdrew because of an adverse 
event (most frequently cough, hyperkalemia, re-
nal dysfunction, or hypotension), with a higher 
rate of withdrawal after adjustment for the short-
er duration of treatment in the enalapril group 
than in the LCZ696 group. After randomization, 
patients in the LCZ696 group were more likely 
than those in the enalapril group to have symp-
tomatic hypotension, but these events rarely re-
quired the discontinuation of treatment (Table 3). 
In contrast, cough, a serum creatinine level of 
2.5 mg per deciliter (221 μmol per liter) or 
more, and a serum potassium level of more than 
6.0 mmol per liter were reported less frequently 
in the LCZ696 group than in the enalapril group 
(P<0.05 for all comparisons) (Table 3). Overall, 
fewer patients in the LCZ696 group than in the 
enalapril group stopped their study medication 
because of an adverse event (10.7% vs. 12.3%, 
P = 0.03) or because of renal impairment (0.7% vs. 
1.4%, P = 0.002). The most frequent serious ad-
verse events and adverse events leading to discon-
tinuation of the study drug are summarized in 
Sections 6 and 7 in the Supplementary Appendix.
As compared with the value at randomization, 
the mean systolic blood pressure at 8 months 
was 3.2±0.4 mm Hg lower in the LCZ696 group 
than in the enalapril group (P<0.001) (Section 8 
in the Supplementary Appendix). However, when 
the between-group difference in blood pressure 
Figure 3 (facing page). Prespecified Subgroup Analyses.
Shown are hazard ratios for the primary end point 
(death from cardiovascular causes or first hospitaliza-
tion for heart failure) and for death from cardiovascu-
lar causes among patients in prespecified subgroups. 
The size of the square corresponds to the number of 
patients in each subgroup. Patients who were not tak-
ing a pretrial angiotensin-converting–enzyme (ACE) 
 inhibitor were taking an angiotensin-receptor blocker 
(except for 20 patients who received neither drug be-
fore the trial). GFR denotes glomerular filtration rate, 
NT-proBNP N-terminal pro–B-type natriuretic peptide, 
and NYHA New York Heart Association.
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was modeled as a time-dependent covariate, it was 
not a determinant of the incremental benefit of 
LCZ696. At 8 months, there were no significant 
changes from baseline in heart rate or serum 
creatinine level between the two groups. Angio-
edema was confirmed by blinded adjudication in 
19 patients in the LCZ696 group and in 10 patients 
in the enalapril group (P = 0.13). No patient had 
airway compromise or required mechanical air-
way protection.
Discussion
In our study involving patients with chronic heart 
failure and a reduced ejection fraction, the inhi-
bition of both the angiotensin II receptor and 
neprilysin with LCZ696 was more effective in re-
ducing the risk of death from cardiovascular causes 
or hospitalization for heart failure than was ACE 
inhibition with enalapril. LCZ696 was also supe-
rior to enalapril in reducing the risk of death 
from any cause and reducing symptoms and 
physical limitations of heart failure. The magni-
tude of these advantages of LCZ696 over ACE in-
hibition was highly significant and clinically im-
portant, particularly since the drug was compared 
with a dose of enalapril that has been shown to 
reduce mortality, as compared with placebo.1,2 
The benefit of LCZ696, which was apparent early 
in the trial, was seen in patients who were al-
ready receiving all other drugs known to improve 
survival among patients with heart failure (i.e., 
beta-blockers and mineralocorticoid-receptor an-
tagonists). The benefit with respect to cardiovas-
cular mortality was consistent in all relevant sub-
groups.
Our study was designed to provide evidence 
to support the replacement of ACE inhibitors or 
ARBs with LCZ696 in the management of chronic 
heart failure. The trial was devised to show an 
advantage with respect to cardiovascular mortality 
alone, which was the primary determinant of the 
sample size and for which a statistically compel-
ling effect was required to stop the trial early 
because of a benefit. Although in clinical prac-
tice, many patients with heart failure receive low 
(and potentially subtherapeutic) doses of ACE 
inhibitors and ARBs,26 we included a run-in pe-
Table 3. Adverse Events during Randomized Treatment.*
Event
LCZ696
(N = 4187)
Enalapril
(N = 4212) P Value
no. (%)
Hypotension
Symptomatic 588 (14.0) 388 (9.2) <0.001
Symptomatic with systolic blood pressure <90 mm Hg 112 (2.7) 59 (1.4) <0.001
Elevated serum creatinine
≥2.5 mg/dl 139 (3.3) 188 (4.5) 0.007
≥3.0 mg/dl 63 (1.5) 83 (2.0) 0.10
Elevated serum potassium
>5.5 mmol/liter 674 (16.1) 727 (17.3) 0.15
>6.0 mmol/liter 181 (4.3) 236 (5.6) 0.007
Cough 474 (11.3) 601 (14.3) <0.001
Angioedema†
No treatment or use of antihistamines only 10 (0.2) 5 (0.1) 0.19
Use of catecholamines or glucocorticoids without 
hospitalization
6 (0.1) 4 (0.1) 0.52
Hospitalization without airway compromise 3 (0.1) 1 (<0.1) 0.31
Airway compromise 0 0 —
* Shown are results of the analyses of prespecified safety events at any time after randomization. The numbers of pa-
tients who permanently discontinued a study drug were as follows: for hypotension, 36 (0.9%) in the LCZ696 group 
and 29 (0.7%) in the enalapril group (P = 0.38); for renal impairment, 29 (0.7%) and 59 (1.4%), respectively (P = 0.002); 
and for hyperkalemia, 11 (0.3%) and 15 (0.4%), respectively (P = 0.56).
† Angioedema was adjudicated in a blinded fashion by an expert committee.
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riod to ensure that LCZ696 would be compared 
with doses of enalapril that have been shown to 
reduce mortality. The mean dose of enalapril 
that was used in our study (18.9 mg daily) was 
higher than or similar to the doses used in the 
two trials that showed a survival benefit with 
enalapril in patients with mild-to-moderate or 
severe symptoms (16.6 mg and 18.4 mg, respec-
tively).1,2
The favorable results of our study contrast with 
the disappointing findings in an earlier large-
scale trial involving patients with heart failure,18 
which showed no significant difference in clini-
cal outcomes between enalapril and omapatrilat 
(a drug that inhibits ACE, neprilysin, and amino-
peptidase P). However, in that trial, omapatrilat 
was given once daily (to reflect its use in patients 
with hypertension), even though its pharmaco-
logic advantages over enalapril in patients with 
heart failure were not maintained throughout the 
24-hour dosing interval.18 This experience led us 
to prescribe LCZ696 twice daily in our study popu-
lation, despite its once-daily efficacy in patients 
with hypertension.21
The superiority of LCZ696 over enalapril was 
not accompanied by important safety concerns; 
fewer patients stopped their study medication 
overall or because of an adverse event in the 
LCZ696 group than in the enalapril group. Be-
cause of its greater vasodilator effects, treatment 
with LCZ696 was associated with a higher rate 
of symptomatic hypotension, but there was no 
increase in the rate of discontinuation because 
of possible hypotension-related adverse effects. 
Although the greater hypotensive effect of LCZ696 
might impair renal perfusion, clinically impor-
tant increases in the serum creatinine level and 
discontinuation of the study drug because of re-
nal impairment were less frequent in the LCZ696 
group than in the enalapril group. These effects 
of LCZ696 on renal function are consistent with 
the effects observed in experimental studies15 
and with the findings in earlier trials of omapa-
trilat.18,22 The main safety concern with omapa-
trilat — life-threatening angioedema — was re-
lated to its inhibition of three enzymes responsible 
for the degradation of bradykinin.27 LCZ696, which 
does not inhibit ACE or aminopeptidase P,19,20 
was not associated with an increased risk of seri-
ous angioedema in our study.
Although we recruited patients with at least 
mildly increased levels of natriuretic peptides in 
order to achieve our projected event rate, the 
characteristics of our patients with heart failure 
were similar to those of study populations in 
other relevant trials and patients in the commu-
nity.24,26,28 During enrollment, we evaluated pa-
tients who were already taking various doses of 
ACE inhibitors or ARBs and required that they 
be able to take the equivalent of a relatively low 
dose of enalapril (10 mg daily) without unac-
ceptable side effects. Doses of the study drugs 
were increased to target levels during the run-in 
phase, primarily to ensure that patients in the 
enalapril group received doses that have been 
shown to reduce mortality.2 Only 12% of pa-
tients did not complete the run-in period be-
cause of adverse events, and the rates of adverse 
events were higher for patients receiving enala-
pril than for those receiving LCZ696. Hence, our 
results are applicable to a broad spectrum of 
patients with heart failure, including those who 
are currently taking an ACE inhibitor or ARB or 
who are likely to be able to take such an agent 
without having unacceptable side effects.
In conclusion, angiotensin receptor–neprily-
sin inhibition with LCZ696 was superior to ACE 
inhibition alone in reducing the risks of death 
and of hospitalization for heart failure. The 
magnitude of the beneficial effect of LCZ696, as 
compared with enalapril, on cardiovascular mor-
tality was at least as large as that of long-term 
treatment with enalapril, as compared with pla-
cebo.2 This robust finding provides strong evi-
dence that combined inhibition of the angioten-
sin receptor and neprilysin is superior to 
inhibition of the renin–angiotensin system alone 
in patients with chronic heart failure.
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